Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia
Open Access
- 24 November 2010
- journal article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 36 (3), 616-626
- https://doi.org/10.1038/npp.2010.193
Abstract
Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially critical outcome variables for assessing antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide polymorphisms (SNPs) in a sample of 738 patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness study. Outcome variables consisted of a neurocognitive battery administered at multiple time points over an 18-month period, measuring processing speed, verbal memory, vigilance, reasoning, and working memory domains. Genetic mediation of improvements in each of these five domains plus a composite neurocognitive measure was assessed for each of five antipsychotics (olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone). Six SNPs achieved genome-wide significance using a pre-specified threshold that ensures, on average, only 1 in 10 findings is a false discovery. These six SNPs were located within, or in close proximity to, genes EHF, SLC26A9, DRD2, GPR137B, CHST8, and IL1A. The more robust findings, that is those significant across multiple neurocognitive domains and having adjacent SNPs showing evidence for association, were rs286913 at the EHF gene (p-value 6.99 × 10(-8), q-value 0.034, mediating the effects of ziprasidone on vigilance), rs11240594 at SLC26A9 (p-value 1.4 × 10(-7), q-value 0.068, mediating the effects of olanzapine on processing speed), and rs11677416 at IL1A (p-value 6.67 × 10(-7), q-value 0.081, mediating the effects of olanzapine on working memory). This study has generated several novel candidate genes for antipsychotic response. However, our findings will require replication and functional validation. To facilitate replication efforts, we provide all GWAS p-values for download.This publication has 78 references indexed in Scilit:
- The Promise and Reality of Pharmacogenetics in PsychiatryPsychiatric Clinics of North America, 2010
- A Genomewide Association Study of Citalopram Response in Major Depressive DisorderBiological Psychiatry, 2010
- Genome-wide pharmacogenomic analysis of response to treatment with antipsychoticsMolecular Psychiatry, 2009
- Common variants on chromosome 6p22.1 are associated with schizophreniaNature, 2009
- A systematic method for estimating individual responses to treatment with antipsychotics in CATIESchizophrenia Research, 2009
- Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysisEuropean Journal of Human Genetics, 2009
- Genome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer DiseaseAmerican Journal of Human Genetics, 2009
- Targeted tandem affinity purification of PSD‐95 recovers core postsynaptic complexes and schizophrenia susceptibility proteinsMolecular Systems Biology, 2009
- Genome-wide association scan for stature in Chinese: evidence for ethnic specific lociHuman Genetics, 2008
- Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in SchizophreniaBiological Psychiatry, 2008